Indivior PLC (LSE: INDV) (“Indivior” or the “Company”) today announced that it has completed the acquisition of Opiant Pharmaceuticals, Inc. (“Opiant”). The transaction strengthens Indivior’s addiction treatment and science portfolio by adding Opiant’s late-stage assets, notably OPNT003, an investigational opioid overdose treatment designed to offer an important treatment option to address the current wave of US opioid overdoses from powerful synthetic opioids, such as fentanyl.
“We are pleased to close our combination with Opiant, which provides us with a comprehensive and relevant treatment platform to address the ongoing U.S. opioid and overdose epidemic,” said Mark Crossley, Chief Executive Officer of Indivior. “We look forward to bringing on Opiant’s talented team and undertaking our shared mission to change patients’ lives through access to life-transforming treatment for substance use disorders.”
Source: Biospace